NN2211-4232 LIRA-PRIME: Efficacy in controlling glycaemia with Victoza (liraglutide) as add-on to metformin vs. OAD's as add-on to metformin after up to 104 weeks of treatment in subjects with type 2 diabetes inadequately controlled with metformin monotherapy and treated in a primary care setting.

  • STATUS
    Recruiting
  • sponsor
    Novo Nordisk
Updated on 23 November 2020

Summary

NN2211-4232 LIRA-PRIME: Efficacy in controlling glycaemia with Victoza (liraglutide) as add-on to metformin vs. OAD's as add-on to metformin after up to 104 weeks of treatment in subjects with type 2 diabetes inadequately controlled with metformin monotherapy and treated in a primary care setting.

Description

A 104 week randomized, phase 4, open-label, active-controlled, multicenter, multinational, parallel-group trial.

Enrollment ends March 2017. A stipend to reimburse for time and travel may be available.

Details
Clinical Study IdentifierTX145559
SponsorNovo Nordisk
Last Modified on23 November 2020

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 0 yrs?
Gender: Male or Female
≥ 18 years of age at the time of signing informed consent
Subjects diagnosed (clinically) with type 2 diabetes mellitus prior to 90 days of screening
On a stable daily dose of metformin as monotherapy ≥1500 mg or maximum tolerated dose documented in the subject medical record within 60 days prior to the day of screening
HbA1C 7.5-9.0% obtained at local laboratory no more than 90 days prior to screening visit
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note